Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Pediatric Adhesion and New Dermal Approach Study
- Conditions
- SyncopePediatricCongenital AthymiaCongenital Heart DiseaseArrhythmiaArrhythmia in Children
- First Posted Date
- 2025-08-12
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- iRhythm Technologies, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT07118124
- Locations
- 🇺🇸
Children's National Hospital, Washington, District of Columbia, United States
🇺🇸St. Luke's Children's Hospital, Boise, Idaho, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
Extended ECG Monitoring in HCM Patients
- Conditions
- Nonsustained Ventricular TachycardiaAtrial FibrillationArrhythmiaHypertrophic CardiomyopathyVentricular Tachycardia
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- iRhythm Technologies, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT04056715
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
True Continuous ECG Monitoring (TCEM Study)
- Conditions
- Cardiac Arrhythmia
- First Posted Date
- 2012-03-21
- Last Posted Date
- 2019-04-18
- Lead Sponsor
- iRhythm Technologies, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT01559246
- Locations
- 🇺🇸
Scripps Health, La Jolla, California, United States
News
USPTO Denies iRhythm Patent Challenges for Vital Signs Monitoring Technology
The US Patent and Trademark Office denied iRhythm Technologies' challenges to four patents covering medical technology for vital signs monitoring, with inventions dating back to 2012.
Turing Medical Appoints Kevin King as CEO to Advance Brain Mapping Technology and Depression Treatment
Turing Medical has appointed Kevin King, former CEO of iRhythm Technologies, as its new President and Chief Executive Officer to accelerate the company's expansion in precision brain mapping technology.
iRhythm Receives FDA 510(k) Clearance for Zio AT Design Modifications
iRhythm Technologies received FDA 510(k) clearance for design modifications to its Zio AT cardiac monitoring system, addressing a prior warning letter.
iRhythm Receives FDA Clearance for Zio AT Enhancements, Faces Delay in Zio MCT Submission
iRhythm Technologies secured FDA 510(k) clearance for design modifications and labeling updates to its Zio AT mobile cardiac telemetry device, addressing concerns from a prior FDA warning letter.
iRhythm Technologies Gains FDA Clearance for Zio AT Device Modifications
iRhythm Technologies secured FDA 510(k) clearance for design modifications and labeling updates to its Zio AT device, used for mobile cardiac telemetry.
iRhythm Technologies Receives FDA Clearance for Zio AT Design Updates, Stock Surges
iRhythm Technologies (IRTC) secured FDA 510(k) clearance for design updates to its Zio AT cardiac monitoring device, addressing prior regulatory concerns.
GUARD-AF Trial: iRhythm's Zio XT Patch Increases AF Detection in Primary Care
The GUARD-AF trial, utilizing iRhythm's Zio XT patch, screened for atrial fibrillation (AF) in primary care settings, increasing new AF diagnoses to 5.0% compared to 3.3% with standard care.